1/14
08:21 pm
mnkd
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile [Yahoo! Finance]
Low
Report
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile [Yahoo! Finance]
1/14
07:36 am
mnkd
MannKind (NASDAQ:MNKD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
MannKind (NASDAQ:MNKD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/8
07:05 pm
mnkd
MannKind Provides Business Updates and 2026 Growth Drivers [Yahoo! Finance]
Low
Report
MannKind Provides Business Updates and 2026 Growth Drivers [Yahoo! Finance]
1/8
01:06 pm
mnkd
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/8
08:05 am
mnkd
MannKind Provides Business Updates and 2026 Growth Drivers
Low
Report
MannKind Provides Business Updates and 2026 Growth Drivers
1/1
06:40 am
mnkd
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care [Yahoo! Finance]
Low
Report
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care [Yahoo! Finance]
12/30
06:47 am
mnkd
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years [Yahoo! Finance]
Low
Report
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years [Yahoo! Finance]
12/23
08:13 am
mnkd
MannKind Shares FUROSCIX® Business Updates [Yahoo! Finance]
Low
Report
MannKind Shares FUROSCIX® Business Updates [Yahoo! Finance]
12/23
08:05 am
mnkd
MannKind Shares FUROSCIX® Business Updates
Low
Report
MannKind Shares FUROSCIX® Business Updates
12/3
05:37 am
mnkd
Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset [Yahoo! Finance]
Low
Report
Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset [Yahoo! Finance]
12/1
08:05 am
mnkd
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
Low
Report
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
11/24
10:02 am
mnkd
MannKind (NASDAQ:MNKD) was given a new $9.00 price target on by analysts at Truist Financial Corporation.
Low
Report
MannKind (NASDAQ:MNKD) was given a new $9.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
mnkd
MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/13
09:53 am
mnkd
MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
Medium
Report
MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
11/11
04:32 pm
mnkd
MannKind to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
Low
Report
MannKind to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
11/11
04:05 pm
mnkd
MannKind to Present at the Jefferies Global Healthcare Conference
Low
Report
MannKind to Present at the Jefferies Global Healthcare Conference
11/11
10:31 am
mnkd
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.50. They now have an "outperform" rating on the stock.
Low
Report
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.50. They now have an "outperform" rating on the stock.
11/11
09:44 am
mnkd
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Wells Fargo & Company from $10.00 to $8.00. They now have an "overweight" rating on the stock.
Low
Report
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Wells Fargo & Company from $10.00 to $8.00. They now have an "overweight" rating on the stock.
11/10
01:22 pm
mnkd
MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript [Seeking Alpha]
Low
Report
MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript [Seeking Alpha]
11/10
01:05 pm
mnkd
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/10
08:40 am
mnkd
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease [Yahoo! Finance]
Medium
Report
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease [Yahoo! Finance]
11/10
08:00 am
mnkd
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
Medium
Report
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
11/8
12:25 pm
mnkd
MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ... [Yahoo! Finance]
Medium
Report
MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ... [Yahoo! Finance]
11/8
11:46 am
mnkd
MannKind (MNKD): Evaluating Valuation After Strong Q3 Revenue Beat and Pipeline Expansion [Yahoo! Finance]
Medium
Report
MannKind (MNKD): Evaluating Valuation After Strong Q3 Revenue Beat and Pipeline Expansion [Yahoo! Finance]
11/6
09:40 pm
mnkd
Will Rising Costs and Revenue Growth Shift MannKind's (MNKD) Long-Term Investment Outlook? [Yahoo! Finance]
Low
Report
Will Rising Costs and Revenue Growth Shift MannKind's (MNKD) Long-Term Investment Outlook? [Yahoo! Finance]